Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis 4Q

Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekt

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

4Q Revenues: $10.1 billion (+1%)
 
4Q Earnings: $1.5 billion (+62%)
 
FY Revenues: $41.5 billion (+9%)
 
FY Earnings: $8.2 billion (+25%)
 
Comments: Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekturna/Rasilez, Exforge, Exjade, Lucentis, Exelon Patch, Tasigna and Xolair. For the year, Gleevec/Glivec sales were $3.7 billion (+15% lc). Zometa sales were $1.4 billion, and Femara and Sandostatin sales were each $1.1 billion. Cardiovascular product sales were $6.7 billion (+10% lc) with new medicines Exforge ($406 million) and Tekturna/Rasilez ($144 million) representing half of that growth. Diovan sales were $5.7 billion (+10% lc). Vaccines and Diagnostics sales for the year were $1.8 billion (+21%). Sandoz sales were $7.6 billion (+5%). Revenues for the quarter and FY were up 8% and 5% in local currencies, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters